Edesa Biotech, Inc. (EDSA)
|Net Income (ttm)||-6.36M|
|Trading Day||January 25|
|Day's Range||5.20 - 5.90|
|52-Week Range||1.64 - 9.45|
TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colom...
TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, ...
Edesa Biotech Inc. (NASDAQ: EDSA) joins the list of COVID-19 stocks, as the company is making headway with regulatory agencies for its late-stage study.
Canadian biopharma Edesa Biotech Inc (NASDAQ: EDSA) is seeing its shares surge higher Monday after it announced regulatory approval to begin a late-stage study of its investigational asset for...
Edesa Biotech received go ahead from FDA to initiate its phase 2b study using EB01 to treat patients with chronic contact dermatitis.
Edesa Biotech (EDSA) stock is flying higher on Thursday after getting approval from the U.S. Food and Drug Administration (FDA).
Edesa Biotech Inc., shares were trading higher Thursday after the company received Food and Drug Administration approval to proceed with its U.S.
Edesa Biotech, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. ... [Read more...]
Dr. Pardeep Nijhawan FRCPC, M.D.
|Stock Exchange |
|Ticker Symbol |
According to one analyst, the rating for Edesa Biotech stock is "Strong Buy" and the 12-month stock price forecast is 15.50.